Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells

Prostate

Volumn 66, Issue 2, 2006, Pages 135-145

  Feldman, Laurie ^a,b   Wang, Yuxun ^a,b   Rhim, Johng S ^c   Bhattacharya, Nandita ^b,d   Loda, Massimo ^b,d   Sytkowski, Arthur J ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Erythropoietin; Erythropoietin receptor; Prostate cancer; STAT5

Indexed keywords

CELL SURFACE RECEPTOR; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; GROWTH FACTOR; STAT5 PROTEIN; STAT5B PROTEIN;

ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; DOSE RESPONSE; ERYTHROID PRECURSOR CELL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTRACELLULAR TRANSPORT; MITOGENESIS; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; ERYTHROPOIETIN, RECOMBINANT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PHOSPHORYLATION; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ERYTHROPOIETIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR;

EID: 31944444232     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20310     Document Type: Article

References (101)

1. Kunikane H, Watanabe K, Fukuoka M, Saijo M, Furuse K, Ikegame H, Ariyoshi Y, Kishimoto S. Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer. Int J Clin Oncol 2001;6(6):296-301.
2. Cazzola M. Mechanisms of anaemia in cancer patients with malignancy: Implications for the clinical use of recombinant human erythropoietin. Med Oncol 2000;17(Supp 1):S11-S16.
3. Horiguchi H, Kayama F, Oguma E, Willmore W, Hradecky P, Bunn H. Cadmium and platinum suppression of erythropoietin production in cell culture: Clinical applications. Blood 2000; 96(12):3742-3747.
4. Thatcher N, DeCampos E, Bell D, Steward W, Varghese G, Morant R, Vansteenkiste J, Rosso R, Ewers S, Sundal E, Schatzmann E, Stocker H. Epoietin alpha prevents anemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer 1999;80(3-4):396-402.
5. Quirt I, Robeson C, Lau C, Kovacs M, Burdette-Radoux S, Dolan S, Tang S, McKenzie M, Couture F. Epoietin alpha therapy increases hemoglobin levels and improves quality of life in patients with cancer related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 2001;19(21):4126-4134.
6. Bottomley A, Thomas R, van Steen K, Flechtner H, Djulbegovic B. Human recombinant erythropoietin and quality of life: A wonder drug or something to wonder about? Lancet Oncol 2002;3(3):145-153.
7. Henke M. Correction of cancer anemia - Impact on disease course, prognosis and treatment efficacy, particularly for patients undergoing radiotherapy. Onkologie 2001;24(5):450-454.
8. Shasha D. The negative impact of anemia on radiotherapy and chemoradiation outcomes. Semin Hematol 2001;38(3 Suppl 7): 8-15.
9. Henke M, Guttenberger R. Erythropoietin in radiation oncology - A review. 1st international conference, Freiburg, June 11-12, 1999. Oncology 2000;58(2):175-182.
10. Shasha D, Harrison LB. Anemia treatment and the radiation oncologist: Optimizing patient outcomes. Oncology (Huntingt) 2001;15(11):1486-1491; discussion 1494-1486.
11. Stuben G, Pottgen C, Knuhmann K, Schmidt K, Stuschke M, Thews O, Vaupel P. Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phys 2003; 55(5):1358-1362.
12. Glaser CM, Millesi W, Kornek GV, Lang S, Schull B, Watzinger F, Selzer E, Lavey RS. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001;50(3):705-715.
13. Sweeney PJ, Nicolae D, Ignacio L, Chen L, Roach M III, Wara W, Marcus KC, Vijayakumar S. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: Final report of a randomized, open-labelled, phase II trial. Br J Cancer 1998;77(11):1996-2002.
14. Feldman L, Sytkowski AJ. Pleiotrophic actions of erythropoietin. Environ Health Prev Med 2003;7:239-245.
15. Lappin TR, Maxwell AP, Johnston PG. EPO's alter ego: Erythropoietin has multiple actions. Stem Cells 2002;20(6):485-492.
16. Sasaki R, Masuda S, Nagao M. Pleiotropic functions and tissue-specific expression of erythropoietin. News Physiol Sci 2001; 16:110-113.
17. Jelkmann W, Wagner K. Beneficial and ominous aspects of the pleiotropic action of erythropoietin. Ann Hematol 2004;83: 673-686.
18. Sigounas G, Salleng K, Mehlhop P, Sallah S, Collins M, Kardatos A, Sigounas D. Erythropoietin inhibits drug-induced fibrosis and improves pulmonary capacity. Blood 2001;98:798a.
19. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-460.
20. Henke M, Laszig R, Rube C, Schafer U, Haase K-D, Schilcher B, Mose S, Beer K, Burger U, Dougherty C, Frommhold H. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Ramdomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
21. Feldman L, Wang Y, Rhim J, Sytkowski A. Human prostate epithelial cells and prostate cancer cells express functional erythropoietin receptors and respond to erythropoietin in vitro. Exp Hematol 2002;30(6 Suppl 1):61.
22. Brower V. Normal and neoplastic prostate cells have EPO receptors. Lancet Oncol 2003;4(2):69.
23. Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A, Onozaki M, Hashimoto M, Musha T, Ogawa K, Fujita H, Nakamura Y, Shiozaki H, Utsumi H. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003;24(6):1021-1029.
24. Arcasoy MO, Jiang X, Haroon ZA. Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res Commun 2003;307(4):999- 1007.
25. Arcasoy M, Amin K, Vollmer R, Jiang X, Demark-Wahnefried W, Haroon Z. Erythropoietin and erythropoietin receptor expression in human prostate cancer. Mod Pathol 2004.
26. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65(1-2):55-63.
27. Romijn J, Verkoelen C, Schroeder F. Application of the MTT assay to human prostate cancer cell lines in vitro: Establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects. Prostate 1988;12(1):99-110.
28. Canada A, Herman L, Kidd K, Robertson C, Trump D. Glutathione depletion increases the cytotoxicity of melphalan to PC-3, an androgen-insensitive prostate cancer cell line. Cancer Chemother Pharmacol 1993;32(1):73-77.
29. Ripple M, Henry W, Rago R, Wilding G. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst 1997;89(1):40-48.
30. Hara I, Miyake H, Hara S, Arakawa S, Kamidono S. Differential involvement of the Fas receptor/ligand system in p53-dependent apoptosis in human prostate cancer cells. Prostate 2000;45(4):341-349.
31. Vetvicka V, Vetvickova J, Fusek M. Role of procathepsin D activation peptide in prostate cancer growth. Prostate 2000; 44(1):1-7.
32. Cardile V, Scifo C, Russo A, Falsaperla M, Morgia G, Motta M, Renis M, Imbriani E, Silvestre G. Involvement of HSP70 in resveratrol-induced apoptosis of human prostate cancer. Anticancer Res 2003;23(6C):4921-4926.
33. Gutierrez-Canas I, Rodriguez-Henche N, Bolanos O, Carmena MJ, Prieto JC, Juarranz MG. VIP and PACAP are autocrine factors that protect the androgen-independent prostate cancer cell line PC-3 from apoptosis induced by serum withdrawal. Br J Pharmacol 2003;139(5):1050-1058.
34. Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 2003; 9(1):370-376.
35. Blaszczyk N, Masri BA, Mawji NR, Ueda T, McAlinden G, Duncan CP, Bruchovsky N, Schweikert H-U, Schnabel D, Jones EC, Sadar MD. Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells. Clin Cancer Res 2004; 10(5):1860-1869.
36. Chung V, Tattersall M, Cheung H. Interactions of a herbal combination that inhibits growth of prostate cancer cells. Cancer Chemother Pharmacol 2004;53(5):384-390.
37. Huang Y, Chueh S, Teng C, Guh J. Investigation of ouabain-induced anticancer effect in human androgen-independent prostate cancer PC-3 cells. Biochem Pharmacol 2004;67(4):727-733.
38. Ioffe M, White E, Nelson D, Dvorzhinski D, DiPaola R. Epothilone induced cytotoxicity is dependent on p53 status in prostate cells. Prostate 2004;61(3):243-247.
39. Kan S, Huang W, Lin L, Wang P. Inhibitory effects of evodiamine on the growth of human prostate cancer cell line LNCaP. Int J Cancer 2004;110(5):641-651.
40. Mochizuki H, Matsubara A, Teishima J, Mutaguchi K, Yasumoto H, Dahiya R, Usui T, Kamiya K. Interaction of ligand-receptor system between stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: A possible predictor of metastasis. Biochem Biophys Res Commun 2004;320(3):656-663.
41. Uzgare AR, Isaacs JT. Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells. Cancer Res 2004;64(17):6190-6199.
42. Showers M, Moreau J, Linnekin D, Druker B, D'Andrea A. Activation of the erythropoietin receptor by the friend spleen focus-forming virus gp55 glycoprotein induces constitutive protein tyrosine phosphorylation. Blood 1992;80(12):3070-3078.
43. Bailey S, Feldman L, Romanowski R, Davis K, Sytkowski A. Anti-peptide antibodies as probes of the recombinant and endogenous murine erythropoietin receptors. Exp Hematol 1993;21:1535-1543.
44. Garraway L, Lin D, Signoretti S, Waltregney D, Dilks D, Bhattacharya N, Loda M. Intermediate basal cells of the prostate: In vitro and in vivo characterization. Prostate 2003;55(3):206-218.
45. Assandri R, Egger M, Gassmann M, Niggli E, Bauer C, Forster I, Gorlach A. Erythropoietin modulates intracellular calcium in a human neuroblastoma cell line. J Physiol 1999;516(Pt 2):343-352.
46. Kaighn ME, Reddel RR, Lechner JF, Peehl DM, Camalier RF, Brash DE, Saffiotti U, Harris CC. Transformation of human neonatal prostate epithelial cells by strontium phosphate transfection with a plasmid containing SV40 early region genes. Cancer Res 1989;49(11):3050-3056.
47. Kuettel MR, Thraves PJ, Jung M, Varghese SP, Prasad SC, Rhim JS, Dritschilo A. Radiation-induced neoplastic transformation of human prostate epithelial cells. Cancer Res 1996;56(1):5-10.
48. Parda DS, Thraves PJ, Kuettel MR, Lee MS, Arnstein P, Kaighn ME, Rhim JS, Dritschilo A. Neoplastic transformation of a human prostate epithelial cell line by the v-Ki-ras oncogene. Prostate 1993;23(2):91-98.
49. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43(4):1809-1818.
50. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17(1):16-23.
51. Yoshimura A, D'Andrea AD, Lodish HF. Friend spleen focus-forming virus glycoprotein gp55 interacts with the erythropoietin receptor in the endoplasmic reticulum and affects receptor metabolism. Proc Natl Acad Sci USA 1990;87(11): 4139-4143.
52. Socolovsky M, Fallon AE, Wang S, Brugnara C, Lodish HF. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/-mice: A direct role for Stat5 in Bcl-X(L) induction. Cell 1999;98(2):181-191.
53. Socolovsky M, Nam H, Fleming MD, Haase VH, Brugnara C, Lodish HF. Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood 2001;98(12):3261-3273.
54. Sawyer ST, Penta K. Association of JAK2 and STAT5 with erythropoietin receptors. Role of receptor phosphorylation in erythropoietin signal transduction. J Biol Chem 1996;271(50): 32430-32437.
55. Oda A, Sawada K, Druker BJ, Ozaki K, Takano H, Koizumi K, Fukada Y, Handa M, Koike T, Ikeda Y. Erythropoietin induces tyrosine phosphorylation of Jak2, STAT5A, and, STAT5B in primary cultured human erythroid precursors. Blood 1998; 92(2):443-451.
56. Suva M, Benito A, Sanz C, Prosper F, Ekhterae D, Nunez G, Fernandez-Luna JL. Erythropoietin Can Induce the Expression of Bcl-xL through Stat5 in Erythropoietin-dependent Progenitor Cell Lines. J Biol Chem 1999;274(32):22165- 22169.
57. Bittorf T, Seiler J, Ludtke B, Buchse T, Jaster R, Brock J. Activation of STAT5 during EPO-directed suppression of apoptosis. Cell Signal 2000;12(1):23-30.
58. Watowich SS, Mikami A, Busche RA, Xie X, Pharr PN, Longmore GD. Erythropoietin receptors that signal through Stat5 or Stat3 support fetal liver and adult erythropoiesis: Lack of specificity of stat signals during red blood cell development. J Interferon Cytokine Res 2000;20(12):1065-1070.
59. Ahonen TJ, Xie J, LeBaron MJ, Zhu J, Nurmi M, Alanen K, Rui H, Nevalainen MT. Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells. J Biol Chem 2003;278(29):27287-27292.
60. Kazansky AV, Spencer DM, Greenberg NM. Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: Evidence from the transgenic adenocarcinoma of the mouse prostate system. Cancer Res 2003;63(24):8757-8762.
61. Juul SE, Yachnis AT, Rojiani AM, Christensen RD. Immunohistochemical localization of erythropoietin and its receptor in the developing human brain. Pediatr Dev Pathol 1999;2(2): 148-158.
62. Cerami A, Brines ML, Ghezzi P, Cerami CJ. Effects of epoetin alfa on the central nervous system. Semin Oncol 2001; 28(2 Suppl 8):66-70.
63. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, Cerami A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000;97(19):10526-10531.
64. Siren AL, Ehrenreich H. Erythropoietin-a novel concept for neuroprotection. Eur Arch Psychiatry Clin Neurosci 2001; 251(4):179-184.
65. Calapai G, Marciano MC, Corica F, Allegra A, Parisi A, Frisina N, Caputi AP, Buemi M. Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur J Pharmacol 2000;401(3):349-356.
66. Juul SE, Ledbetter DJ, Joyce AE, Dame C, Christensen RD, Zhao Y, DeMarco V. Erythropoietin acts as a trophic factor in neonatal rat intestine. Gut 2001;49(2):182-189.
67. Juul SE, Joyce AE, Zhao Y, Ledbetter DJ. Why is erythropoietin present in human milk? Studies of erythropoietin receptors on enterocytes of human and rat neonates. Pediatr Res 1999;46(3): 263-268.
68. Ledbetter DJ, Juul SE. Erythropoietin and the incidence of necrotizing enterocolitis in infants with very low birth weight. J Pediatr Surg 2000;35(2):178-181; discussion 182.
69. Masuda S, Kobayashi T, Chikuma M, Nagao M, Sasaki R. The oviduct produces erythropoietin in an estrogen- and oxygen-dependent manner. Am J Physiol Endocrinol Metab 2000;278(6):E1038-E1044.
70. Yasuda Y, Masuda S, Chikuma M, Inoue K, Nagao M, Sasaki R. Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem 1998; 273(39):25381-25387.
71. Yasuda Y, Fujita Y, Musha T, Tanaka H, Shiokawa S, Nakamatsu K, Mori S, Matsuo T, Nakamura Y. Expression of erythropoietin in human female reproductive organs. Ital J Anat Embryol 2001;106(2 Suppl 2):215-222.
72. Cai ZP, Manalo DJP, Wei GMDP, Rodriguez ERMD, Fox-Talbot KMA, Lu HMDP, Zweier JLMD, Semenza GLMDP. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation July 8 2003;108(1):79-85.
73. Arcasoy MO, Amin K, Haroon ZA. Erythropoietin (EPO) stimulates angiogenesis and promotes wound healing. Blood 2001;98:822a.
74. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, Verma A. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001;61(9):3561-3565.
75. Acs G, Zhang PJ, Rebbeck TR, Acs P, Verma A. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 2002;95(5):969-981.
76. Bunworasate U, Arnouk H, Minderman H, O'Loughlin KL, Sait SN, Barcos M, Stewart CC, Baer MR. Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia. Blood 2001;98(12):3492-3494.
77. Arcasoy MO, Amin K, Karayal AF, Chou SC, Raleigh JA, Varia MA, Haroon ZA. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 2002;82(7): 911-918.
78. Yasuda Y, Fujita Y, Masuda S, Musha T, Ueda K, Tanaka H, Fujita H, Matsuo T, Nagao M, Sasaki R, Nakamura Y. Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis 2002;23(11):1797-1805.
79. Yasuda Y, Musha T, Tanaka H, Fujita Y, Fujita H, Utsumi H, Matsuo T, Masuda S, Nagao M, Sasaki R, Nakamura Y. Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer 2001; 84(6):836-843.
80. McMahon F, Vargas R, Ryan M, Jain A, Abels RI, Perry B, Smith I. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990;76(9):1718-1722.
81. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990;87(15):5978-5982.
82. Masuda S, Nagao M, Takahata K, Konishi Y, Gallyas F Jr., Tabira T, Sasaki R. Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem 1993;268(15):11208-11216.
83. Batra S, Perelman N, Luck N, Shimada H, Malik P. Pediatric tumors express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 2003;83(10):1477-1487.
84. Tsushima H, Urata Y, Miyazaki Y, Fuchigami K, Kuriyama K, Kondo T, Tomonaga M. Human erythropoietin receptor increases GATA-2 and Bcl-xL by a protein kinase C-dependent pathway in human erythropoietin-dependent cell line AS-E2. Cell Growth Differ 1997;8(12):1317-1328.
85. Gregory T, Yu C, Ma A, Orkin SH, Blobel GA, Weiss MJ. GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression. Blood 1999; 94(1):87-96.
86. Dolznig H, Habermann B, Stangl K, Deiner EM, Moriggl R, Beug H, Mullner EW. Apoptosis protection by the Epo target Bcl-XL allows factor-independent differentiation of primary erythroblasts. Curr Biol 2002;12(13):1076-1085.
87. Hafid-Medheb K, Augery-Bourget Y, Minatchy M-N, Hanania N, Robert-Lezenes J. Bcl-XL is required for heme synthesis during the chemical induction of erythroid differentiation of murine erythroleukemia cells independently of its antiapoptotic function. Blood 2003;101(7):2575-2583.
88. Haughn L, Hawley RG, Morrison DK, von Boehmer H, Hockenbery DM. BCL-2 and BCL-XL restrict lineage choice during hematopoietic differentiation. J Biol Chem 2003; 278(27):25158-25165.
89. Mori M, Uchida M, Watanabe T, Kirito K, Hatake K, Ozawa K, Komatsu N. Activation of extracellular signal-regulated kinases ERK1 and ERK2 induces Bcl-xL up-regulation via inhibition of caspase activities in erythropoietin signaling. J Cell Physiol 2003;195(2):290-297.
90. Spentzos D, Sytkowski AJ. Clinical applications of recombinant human erythropoietin. In: Dembowsky K, Stadler P, editors. Novel therapeutic proteins. Weinheim: Wiley-VCH. 2000. pp 29-57.
91. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 1994;91(9): 3974-3978.
92. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999; 91(19):1616-1634.
93. Fodinger M, Fritsche-Polanz R, Buchmayer H, Skoupy S, Sengoelge G, Horl WH, Sunder-PlassmannG. Erythropoietin-inducible immediate-early genes in human vascular endothelial cells. J Investig Med 2000;48(2):137-149.
94. Carlini RG, Reyes AA, Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 1995;47(3):740-745.
95. Pirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 2000;44(1):77-87.
96. Berruti A, Dogliotti L, Bitossi R, Fasolis G, Gorzegno G, Bellina M, Torta M, Porpiglia F, Fontana D, Angeli A. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: Predictive role of bone resorption and formation markers evaluated at baseline. J Urol 2000;164(4):1248-1253.
97. Geldof AA. Models for cancer skeletal metastasis: A reappraisal of Batson's plexus. Anticancer Res 1997;17(3A):1535-1539.
98. Suzuki T, Shimizu T, Kurokawa K, Jimbo H, Sato J, Yamanaka H. Pattern of prostate cancer metastasis to the vertebral column. Prostate 1994;25(3):141-146.
99. Nishijima Y, Uchida K, Koiso K, Nemoto R. Clinical significance of the vertebral vein in prostate cancer metastasis. Adv Exp Med Biol 1992;324:93-100.
100. Sytkowski AJ, O'Hara C, Vanasse G, Armstrong MJ, Kreczko S, Dainiak N. Characterization of biologically active, platelet-derived growth factor-like molecules produced by murine erythroid cells in vitro and in vivo. J Clin Invest 1990;85(1):40-46.
101. Keutzer JC, Sytkowski AJ. Regulated production of a pleiotropic cytokine-platelet-derived growth factor by differentiating erythroid cells in vitro and in vivo. Proc Natl Acad Sci USA 1995;92(11):4967-4971.